Abstract
After the intravenous (IV) injection of endotoxin, (lipopolysaccharide [LPS]), in the rat, interleukin-1 alpha/beta (IL-1 alpha/beta) mRNA expression peaks at 1 hour in whole organ RNA preparations of the lung, liver, spleen, and bowel. Interleukin-1 receptor antagonist (IL-1ra) mRNA peaks at 2 to 4 hours, consistent with the hypothesis that IL-1ra acts as an endogenous negative feedback mechanism to downregulate the proinflammatory effects of IL-1. After the intratracheal (IT) injection of LPS, however, IL-1 and IL-1ra mRNA levels in whole lung peak at 6 hours, concurrent with the maximum influx of neutrophils (PMNs) into the bronchoalveolar space. To address the cellular source of IL-1 and IL-1ra mRNA in the lung during acute pneumonitis, mRNA levels were studied in bronchoalveolar lavage (BAL) macrophages incubated with LPS in vitro for 6 hours as compared with BAL cells (95% PMNs) obtained 6 hours after IT injection of LPS. A much greater expression of IL-1 and IL-1ra mRNA was observed in PMN-rich BAL cells obtained after IT injection of LPS, suggesting that PMNs contribute substantially to IL-1 and IL-1ra mRNA expression. Fractionation of alveolar macrophage-enriched and PMN-enriched subpopulations from the BAL cells obtained at 6 hours after IT injection of LPS confirmed that neutrophils are a source of IL-1 and IL-1ra mRNA. The difference in the kinetics of IL-1 and IL-1ra mRNA expression in whole lung RNA preparations after IV and IT injections of LPS is due to the contribution of PMNs that appear in the lung in large numbers after IT injection. Finally, human peripheral blood PMNs were found to express IL-1ra mRNA and protein after in vitro incubation with LPS. PMNs may contribute to the up- and downregulation of their own accumulation by expressing both IL-1 and IL-1ra.
MeSH Terms
Animals
Bronchoalveolar Lavage Fluid/chemistry,pathology
Cytokines/genetics
Down-Regulation/drug effects,genetics
Endotoxins/blood,pharmacology
Gene Expression/drug effects
Inflammation/genetics
Interleukin 1 Receptor Antagonist Protein
Interleukin-1/genetics
Lipopolysaccharides/physiology
Liver/chemistry,drug effects,pathology
Macrophages/chemistry,drug effects,pathology
Male
Proteins/genetics
RNA, Messenger/analysis,genetics
Rats
Rats, Inbred Lew
Recombinant Proteins/genetics
Sialoglycoproteins
Spleen/chemistry,drug effects,pathology
Up-Regulation/drug effects,genetics
Chemicals
Cytokines
Endotoxins
IL1RN protein, human
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Lipopolysaccharides
Proteins
RNA, Messenger
Recombinant Proteins
Sialoglycoproteins
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Ulich T R
Department of Pathology, University of California, San Diego School of Medicine 92103.
Guo K
Yin S
del Castillo J
Yi E S
Thompson R C
Eisenberg S P
References (17)
17 references, click to expand
-
Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.
J Clin Invest. 1990 May;85(5):1694-7
PMID: 2139669
-
Inducible interleukin-1 gene expression in human vascular smooth muscle cells.
J Clin Invest. 1986 Dec;78(6):1432-8
PMID: 3491091
-
Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression.
Am J Pathol. 1990 Nov;137(5):1173-85
PMID: 2240164
-
Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram-negative infection.
Lab Invest. 1988 Apr;58(4):365-78
PMID: 3282123
-
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
J Exp Med. 1986 Jun 1;163(6):1433-50
PMID: 3486936
-
cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.
Proc Natl Acad Sci U S A. 1991 May 1;88(9):3681-5
PMID: 1827201
-
Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6.
J Immunol. 1991 Apr 1;146(7):2316-23
PMID: 2005401
-
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.
Nature. 1990 Jan 25;343(6256):336-40
PMID: 2137200
-
Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.
Nature. 1990 Jan 25;343(6256):341-6
PMID: 2137201
-
Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.
Nature. 1990 Dec 6;348(6301):550-2
PMID: 2147233
-
The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation.
Am J Pathol. 1991 Mar;138(3):521-4
PMID: 1825745
-
The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate.
Am J Pathol. 1991 Jun;138(6):1485-96
PMID: 2053596
-
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.
J Clin Invest. 1990 Sep;86(3):972-80
PMID: 2168444
-
Cytokine regulation of IL-1 beta gene expression in the human polymorphonuclear leukocyte.
J Immunol. 1990 Nov 1;145(9):2932-7
PMID: 2212667
-
Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.
J Immunol. 1989 Apr 1;142(7):2321-4
PMID: 2784459
-
Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes.
J Immunol. 1987 Nov 15;139(10):3406-15
PMID: 3316383
-
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.
J Immunol. 1990 Dec 15;145(12):4181-4
PMID: 2147937